5-(4-bromophenyl)-5-ethylimidazolidine-2,4-dione | 78630-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 5-(4-bromophenyl)-5-ethylimidazolidine-2,4-dione
• 英文别名: 5-ethyl-5-(4-bromo-phenyl)-imidazolidine-2,4-dione；5-Aethyl-5-(4-brom-phenyl)-imidazolidin-2,4-dion；5-(4-bromo-phenyl)-5-ethyl-imidazolidine-2,4-dione
• CAS: 78630-35-0
• 化学式: C₁₁H₁₁BrN₂O₂
• mdl: MFCD09741413
• 分子量: 283.125
• InChiKey: FNBXHQSJHUSACN-UHFFFAOYSA-N

物化性质

• 熔点：
  223-224 °C
• 密度：
  1.488±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-bromophenyl)-5-ethylimidazolidine-2,4-dione 、 2-溴-2',4'-二氟苯乙酮 在 potassium carbonate 作用下， 以61%的产率得到5-(4-bromophenyl)-3-(2-(2,4-difluorophenyl)-2-oxoethyl)-5-ethylimidazolidine-2,4-dione
  参考文献：
  名称：

  Identification and Profiling of Hydantoins—A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

  摘要：

  Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-beta-D-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.

  DOI：

  10.1021/acs.jmedchem.8b01356
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 盐酸 作用下， 生成 5-(4-bromophenyl)-5-ethylimidazolidine-2,4-dione
  参考文献：
  名称：

  DE1017172

  摘要：

  公开号：

文献信息

• Hydantoins having RNase modulatory activity
  申请人：Olson W. Matthew

  公开号：US20050203156A1

  公开（公告）日：2005-09-15

  The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the hydantoin derivatives, including the treatment of HIV, AIDS and retrovirus-associated cancer.

  本发明涉及具有RNase H、聚合酶和/或HIV逆转录酶调节活性，特别是抑制活性的咪唑烷酮衍生物。该发明包括咪唑烷酮衍生物、含有这些衍生物的组合物、合成这些衍生物的方法、筛选方法以识别这些衍生物，以及使用这些咪唑烷酮衍生物进行治疗的方法，包括治疗HIV、艾滋病和逆转录病毒相关癌症的方法。
• Solvent effects on the absorption spectra of potentially pharmacologically active 5-alkyl-5-arylhydantoins: A structure-property relationship study
  作者：Sleem Hmuda、Nebojsa Banjac、Nemanja Trisovic、Bojan Bozic、Natasa Valentic、Gordana Uscumlic

  DOI：10.2298/jsc120719118h

  日期：——

  To obtain an insight into the interactions of potential anticonvulsant drugs with their surrounding, two series of 5-methyl-5-aryl- and 5-ethyl-5-arylhydantoins were synthesized and their absorption spectra were recorded in the region from 200 to 400 nm in a set of selected solvents. The effects of solvent dipolarity/polarizability and solvent-solute hydrogen bonding interactions on the absorption maxima shifts were analyzed by means of the linear solvation energy relationship (LSER) concept of Kamlet and Taft. The ratio of the contributions of specific and nonspecific solvent-solute interactions were correlated with the corresponding ADME properties of the studied compounds. The correlation equations were combined with different physicochemical parameters to generate new equations, which demonstrate the reasonable relationships between solvent-solute interactions and the structure-activity parameters.

  为了深入了解潜在抗惊厥药物与周围环境的相互作用 的相互作用，合成了两个系列的 5-甲基-5-芳基和 5-乙基-5-芳基海因 合成了两个系列的 5-甲基-5-芳基和 5-乙基-5-芳基hydantoins，并在一组选定的溶剂中记录了它们在 200 至 400 纳米区域的吸收光谱。 在一组选定溶剂中记录了它们在 200 至 400 nm 波段的吸收光谱。溶剂的 溶剂的偶极性/极化性和溶剂-溶质氢键相互作用对吸收最大值偏移的影响。 通过线性溶解能关系分析了溶剂二极性/极化性和溶剂-溶剂氢键相互作用对吸收最大值移动的影响。 的线性溶解能关系（LSER）概念进行了分析。 塔夫脱的线性溶解能关系（LSER）概念进行了分析。特异性和非特异性 与所研究化合物相应的 ADME 相关。相关方程 与不同的理化参数相结合，生成了新的方程。 证明了溶剂-溶质相互作用与结构-活性参数之间的合理关系。 与结构-活性参数之间的合理关系。
• Hydantoins Having RNase Modulatory Activity
  申请人：Olson Matthew W.

  公开号：US20100063118A1

  公开（公告）日：2010-03-11

  The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the hydantoin derivatives, including the treatment of HIV, AIDS and retrovirus-associated cancer.

  本发明涉及具有RNase H、聚合酶和/或HIV反转录酶调节活性的咪唑二酮衍生物，特别是具有抑制活性的咪唑二酮衍生物。该发明包括咪唑二酮衍生物、含有该衍生物的组合物、合成该衍生物的方法、筛选识别该衍生物的方法以及使用咪唑二酮衍生物的治疗方法，包括治疗HIV、艾滋病和逆转录病毒相关癌症的方法。
• [EN] HYDANTOINS HAVING RNase MODULATORY ACTIVITY<br/>[FR] HYDANTOINES A ACTIVITE MODULATRICE DE LA RNASE
  申请人：WYETH CORP

  公开号：WO2005090316A1

  公开（公告）日：2005-09-29

  The present invention relates to hydantoin derivatives having RNase H, polymerase and/or HIV reverse transcriptase modulatory, and particularly, inhibitory activity. Included in the invention are the hydantoin derivatives, compositions containing the derivatives, methods of synthesis of the derivatives, screening methods to identify the derivatives, and methods of treatment using the hydantoin derivatives, including the treatment of HIV, AIDS and retrovirus­associated cancer.